Eur J Clin Invest. 2020 Jul 23:e13358. doi: 10.1111/eci.13358. Online ahead of print.
ABSTRACT
The use of hydroxychloroquine (HCQ) has been considered a therapeutic option by international guidelines and expert opinions during the first phase of COVID-19 pandemics, 1-10 although scientific evidence remained too scarce to make a definitive recommendation 11 . While HCQ use has now been questioned by recent data 7 , some previous works draw attention to contrasting results on enhanced viral clearance after HCQ treatment 1-6,10 .
PMID:32705683 | DOI:10.1111/eci.13358